270 related articles for article (PubMed ID: 38329361)
21. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.
Bongomin F; Oladele RO; Gago S; Moore CB; Richardson MD
Mycoses; 2018 May; 61(5):290-297. PubMed ID: 29377368
[TBL] [Abstract][Full Text] [Related]
22. Proteome and secretome profiling of zinc availability in Cryptococcus neoformans identifies Wos2 as a subtle influencer of fungal virulence determinants.
Ball B; Woroszchuk E; Sukumaran A; West H; Afaq A; Carruthers-Lay D; Muselius B; Gee L; Langille M; Pladwig S; Kazi S; Hendriks A; Geddes-McAlister J
BMC Microbiol; 2021 Dec; 21(1):341. PubMed ID: 34903172
[TBL] [Abstract][Full Text] [Related]
23. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
[TBL] [Abstract][Full Text] [Related]
24. Proteomics of
Muselius B; Durand SL; Geddes-McAlister J
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830272
[TBL] [Abstract][Full Text] [Related]
25. An Antivirulence Approach for Preventing Cryptococcus neoformans from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease.
Aaron PA; Vu K; Gelli A
mBio; 2020 Jul; 11(4):. PubMed ID: 32694141
[No Abstract] [Full Text] [Related]
26. Berberine Antifungal Activity in Fluconazole-Resistant Pathogenic Yeasts: Action Mechanism Evaluated by Flow Cytometry and Biofilm Growth Inhibition in Candida spp.
da Silva AR; de Andrade Neto JB; da Silva CR; Campos Rde S; Costa Silva RA; Freitas DD; do Nascimento FB; de Andrade LN; Sampaio LS; Grangeiro TB; Magalhães HI; Cavalcanti BC; de Moraes MO; Nobre Júnior HV
Antimicrob Agents Chemother; 2016 Jun; 60(6):3551-7. PubMed ID: 27021328
[TBL] [Abstract][Full Text] [Related]
27. A ketogenic diet enhances fluconazole efficacy in murine models of systemic fungal infection.
Palmucci JR; Sells BE; Giamberardino CD; Toffaletti DL; Dai B; Asfaw YG; Dubois LG; Li Z; Theriot B; Schell WA; Hope W; Tenor JL; Perfect JR
mBio; 2024 May; 15(5):e0064924. PubMed ID: 38619236
[TBL] [Abstract][Full Text] [Related]
28. Antifungal Peptide SP1 Damages Polysaccharide Capsule of Cryptococcus neoformans and Enhances Phagocytosis of Macrophages.
Liu Y; Zhang Y; Zhao X; Lu W; Zhong Y; Fu YV
Microbiol Spectr; 2023 Mar; 11(2):e0456222. PubMed ID: 36916981
[TBL] [Abstract][Full Text] [Related]
29. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
[TBL] [Abstract][Full Text] [Related]
30. Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole.
Agudelo CA; Muñoz C; Ramírez A; Tobón AM; de Bedout Bact C; Cano LE; Restrepo A
Rev Iberoam Micol; 2015; 32(4):214-20. PubMed ID: 25637338
[TBL] [Abstract][Full Text] [Related]
31. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
[TBL] [Abstract][Full Text] [Related]
32. Discovery of New Tricyclic Oxime Sampangine Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcosis and Candidiasis.
Yang W; Liu R; Li Z; Tu J; Xu D; Liu N; Sheng C
J Med Chem; 2024 Mar; 67(6):4726-4738. PubMed ID: 38489247
[No Abstract] [Full Text] [Related]
33. Ergosterol distribution controls surface structure formation and fungal pathogenicity.
Choy HL; Gaylord EA; Doering TL
mBio; 2023 Aug; 14(4):e0135323. PubMed ID: 37409809
[TBL] [Abstract][Full Text] [Related]
34. In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans.
Tan L; Shi H; Chen M; Wang Z; Yao Z; Sun Y
J Mycol Med; 2022 Mar; 32(1):101227. PubMed ID: 34800920
[TBL] [Abstract][Full Text] [Related]
35. Cross-Kingdom Infection of Macrophages Reveals Pathogen- and Immune-Specific Global Reprogramming and Adaptation.
Sukumaran A; Ball B; Krieger JR; Geddes-McAlister J
mBio; 2022 Aug; 13(4):e0168722. PubMed ID: 35862772
[TBL] [Abstract][Full Text] [Related]
36. The antifungal and Cryptococcus neoformans virulence attenuating activity of Pelargonium sidoides extracts.
Samie S; Trollope KM; Joubert LM; Makunga NP; Volschenk H
J Ethnopharmacol; 2019 May; 235():122-132. PubMed ID: 30738119
[TBL] [Abstract][Full Text] [Related]
37. Disarming Fungal Pathogens:
Mayer FL; Kronstad JW
mBio; 2017 Oct; 8(5):. PubMed ID: 28974618
[TBL] [Abstract][Full Text] [Related]
38. Antimalarials and amphotericin B interact synergistically and are new options to treat cryptococcosis.
Freitas GJC; Ribeiro NQ; Gouveia-Eufrasio L; Emidio ECP; Guimarães GM; César IC; Paixão TA; Oliveira JBS; Caza M; Kronstad JW; Santos DA
Int J Antimicrob Agents; 2023 Jul; 62(1):106807. PubMed ID: 37030471
[TBL] [Abstract][Full Text] [Related]
39. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Khyriem AB; Sujatha S; Parija SC
Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
[TBL] [Abstract][Full Text] [Related]
40. Amino acid substitution in Cryptococcus neoformans lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates.
Bosco-Borgeat ME; Mazza M; Taverna CG; Córdoba S; Murisengo OA; Vivot W; Davel G
Rev Argent Microbiol; 2016; 48(2):137-42. PubMed ID: 27311753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
